What is Tonix Pharmaceuticals Holding Days Payable?
Tonix Pharmaceuticals HoldingFRA:TPM0 -3.13%9 Days Payable is 510.57 as of Mar. 2026, which is 47% above its 10-year median of 347.96. GuruFocus rates FRA:TPM0 with a GF Score™ of 9/100 and a GF Value™ of €1.44 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 700 Biotechnology companies, Tonix Pharmaceuticals Holding ranks better than 75.14% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TPM0 vs ALEC, IMUX, WHWK: Days Payable Comparison
For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tonix Pharmaceuticals Holding Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Days Payable distribution charts can be found below:
* The bar in red indicates where Tonix Pharmaceuticals Holding's Days Payable falls into.
Tonix Pharmaceuticals Holding Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tonix Pharmaceuticals Holding (FRA:TPM0) has a Days Payable of 510.57 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tonix Pharmaceuticals Holding and its competitors. This is 47% above median its historical median of 347.96. Over the past decade, Tonix Pharmaceuticals Holding's Days Payable has ranged from 195.73 to 456.15. According to the industry distribution chart, Tonix Pharmaceuticals Holding ranks #174 out of 700 companies in the Biotechnology industry, placing it in the top 24.9%.
Is Tonix Pharmaceuticals Holding's Days Payable too high?
Tonix Pharmaceuticals Holding's current Days Payable of 510.57 is 47% above median its 10-year median of 347.96. Over the past 10 years, this metric has ranged from a low of 195.73 to a high of 456.15. The Biotechnology industry median Days Payable is 112.83. Tonix Pharmaceuticals Holding's value of 510.57 is 352.5% above this industry median. Based on the distribution chart, Tonix Pharmaceuticals Holding ranks #174 out of 700 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Days Payable compare to ALEC and IMUX?
According to the Biotechnology industry distribution chart, Tonix Pharmaceuticals Holding ranks #174 out of 700 companies for Days Payable. This places Tonix Pharmaceuticals Holding in the top 25% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.83. Tonix Pharmaceuticals Holding's value of 510.57 is 352.5% above this benchmark. Historically, Tonix Pharmaceuticals Holding's own Days Payable has ranged from 195.73 to 456.15 over the past decade. While the company's 10-year median is 347.96 vs. the industry median of 112.83, Tonix Pharmaceuticals Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tonix Pharmaceuticals Holding's current Days Payable of 510.57 is 352.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tonix Pharmaceuticals Holding and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tonix Pharmaceuticals Holding's current Days Payable is 510.57, which is 47% above median its own 10-year median of 347.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (FRA:TPM0) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.44, compared to a current price of €10.52 — trading 630.2% above its estimated fair value. The current Days Payable is 510.57, which is 47% above median its 10-year median of 347.96 and 352.5% above the Biotechnology industry median of 112.83. Tonix Pharmaceuticals Holding's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (FRA:TPM0), the current Days Payable is 510.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tonix Pharmaceuticals Holding (FRA:TPM0) Overvalued in 2026?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued.
The current stock price of €10.52 is trading 630.2% above its estimated GF Value™ of €1.44.
GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.
Key valuation signals for FRA:TPM0:
Days Payable: 510.57 (47% above median its 10-year median of 347.96)
GF Value™: €1.44 vs. price of €10.52 (630.2% above fair value)
Industry Position: 352.5% above the Biotechnology median (#174 of 700)
No single metric tells the full story. See the FRA:TPM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tonix Pharmaceuticals Holding Business Description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
9GF Score
Get the complete analysis for FRA:TPM0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TPM0 has been successfully added to your 
